Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 18/20 | 0.71 |
| ▸ | ACE | P12821 | 1/20 | 0.68 |
| ▸ | ECE1 | P42892 | 1/20 | 0.68 |
| ▸ | XRCC6 | P12956 | 1/20 | 0.63 |
| ▸ | XRCC5 | P13010 | 1/20 | 0.63 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7323684 | 0.89 | PRKDC (0.68) | PRKDCACEECE1XRCC6XRCC5 | |
| SCHEMBL7323875 | 0.83 | PRKDC (0.71) | PRKDCACEECE1XRCC6XRCC5 | |
| SCHEMBL31061328 | 0.83 | PRKDC (1.00) | PRKDCACEECE1XRCC6XRCC5 | |
| SCHEMBL3533604 | 0.83 | PRKDC (1.00) | PRKDCACEECE1XRCC6XRCC5 | |
| SCHEMBL3536694 | 0.82 | PRKDC (1.00) | PRKDCP2RY12 | |
| SCHEMBL31061046 | 0.82 | PRKDC (1.00) | PRKDCP2RY12 | |
| SCHEMBL30218216 | 0.81 | PRKDC (1.00) | PRKDCACEECE1XRCC6XRCC5 | |
| SCHEMBL3361567 | 0.81 | PRKDC (1.00) | PRKDCACEECE1XRCC6XRCC5 | |
| SCHEMBL13435723 | 0.80 | PRKDC (0.81) | PRKDCACEECE1XRCC6XRCC5 | |
| SCHEMBL3537736 | 0.79 | PRKDC (1.00) | PRKDCP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5703075-A | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-30 | — | — | US | claimed |
| EP-0459983-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | PHARMACIA & UPJOHN COMPANY (US) | 1991-12-11 | — | — | EP | claimed |
| WO-1990006921-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | claimed |
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-5703075-A | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0459983-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | PHARMACIA & UPJOHN COMPANY (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1990006921-A1 | ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | PRKDC 212/4885ACE 2658/4885ECE1 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.